Nikolai Podoltsev, MD, PhD
Associate Professor of Internal Medicine (Hematology)Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Duffy Firm Chief for Education, Department of Internal Medicine
Associate Director of the Hematology/Oncology Fellowship Program, Department of Internal Medicine
Clinical Director, Malignant Hematology, Department of Internal Medicine, Division of Malignant Hematology
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Duffy Firm Chief for Education, Department of Internal Medicine
Associate Director of the Hematology/Oncology Fellowship Program, Department of Internal Medicine
Clinical Director, Malignant Hematology, Department of Internal Medicine, Division of Malignant Hematology
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Duffy Firm Chief for Education, Department of Internal Medicine
Associate Director of the Hematology/Oncology Fellowship Program, Department of Internal Medicine
Clinical Director, Malignant Hematology, Department of Internal Medicine, Division of Malignant Hematology
Contact Info
About
Titles
Associate Professor of Internal Medicine (Hematology)
Duffy Firm Chief for Education, Department of Internal Medicine; Associate Director of the Hematology/Oncology Fellowship Program, Department of Internal Medicine; Clinical Director, Malignant Hematology, Department of Internal Medicine, Division of Malignant Hematology
Biography
Dr. Nikolai Podoltsev is an Associate Professor of Medicine (Hematology). His practice is focused on management of patients with acute leukemias, including acute myeloid leukemias (AML) and acute lymphoblastic leukemia (ALL) as well as myeloid neoplasms like myelodisplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs), such as polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF), and chronic myeloid leukemia (CML) among others. He also provides care for patients with aplastic anemia and bone marrow failure syndromes and follows patients with clonal hematopoiesis of indeterminate potential (CHIP), and systemic mastocytosis and hypereosinophilic syndrome. He is the director of the Hematology/Leukemia Tumor Board.
As the Associate Director of the Yale Hematology/Oncology Fellowship Program and Yale-New Haven Hospital Duffy Firm Chief for Education, Dr. Podoltsev is involved in organizing and providing hematology education for hematology/medical oncology fellows, internal medicine residents, and medical students. The Yale Cancer Outcomes Public Policy and Effectiveness Research (COPPER) Center membership helps Dr. Podoltsev to study epidemiology, and the patterns of care and outcomes of patients with hematological malignancies. Dr. Podoltsev is engaged in the clinical research programs of the Leukemia Clinical Research Team as a Principal Investigator for multiple clinical trials enrolling patients with acute leukemias and myeloid malignancies.
Appointments
Hematology
Associate Professor on TermPrimary
Other Departments & Organizations
- Developmental Therapeutics
- Hematology
- Internal Medicine
- Leukemia & Lymphoma Program
- Yale Cancer Center
- Yale Medicine
- Yale Ventures
Education & Training
- Fellow
- Yale University School of Medicine (2010)
- Chief Resident
- Hospital of St Raphael (2001)
- Resident
- Hospital of St Raphael (2000)
- Fellow
- St. Petersburg State Pavlov Medical University (1997)
- PhD
- Pavlov First State Medical University of St. Petersburg (1997)
- Resident
- St. Petersburg State Pavlov Medical University (1995)
- MD
- Pavlov First State Medical University of St. Petersburg (1993)
Research
Overview
Management of Malignant Hematology - Older Adult Focus; Myeloprolipherative Neoplasms
Medical Research Interests
ORCID
0000-0002-3657-778X
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Amer Zeidan, MBBS
Scott Huntington, MD, MPH, MSc
Xiaomei Ma, PhD
Rory Shallis, MD
Rong Wang, PhD
Jan Philipp Bewersdorf, MD, FACP
Myelodysplastic Syndromes
Myeloproliferative Disorders
Leukemia
Publications
2024
Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML
Alhajahjeh A, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Goshua G, Bewersdorf J, Zeidan A. Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML. Leukemia & Lymphoma 2024, ahead-of-print: 1-9. PMID: 39560957, DOI: 10.1080/10428194.2024.2426073.Peer-Reviewed Original ResearchAltmetricConceptsConventional care regimensOlder patientsTreatment of older patientsIDH2 inhibitor enasidenibIncremental cost-effectiveness ratioCost-effectiveness ratioProbabilistic sensitivity analysesR/R AMLRefractory/relapsed AMLEvent-freeCost-effective treatmentEnasidenibCare regimensAMLPatientsCost-effectiveIncremental costLife yearsConventional careR/RIncremental effectSurvivalTreatmentA review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS
Norman M, Yamartino K, Gerstein R, Shallis R, Mendez L, Podoltsev N, Stahl M, Eighmy W, Zeidan A. A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS. Expert Review Of Hematology 2024, 17: 755-767. PMID: 39474840, DOI: 10.1080/17474086.2024.2422554.Peer-Reviewed Original ResearchConceptsDiagnosed AMLSurvival benefitManagement of acute myeloid leukemiaDevelopment of oral therapiesIsocitrate dehydrogenase inhibitorsNewly diagnosed AMLManagement of adult patientsPost-transplant maintenanceAcute myeloid leukemiaSingle-arm studyExcellent response ratesIDH inhibitorsRelapsed AMLHypomethylating agentsInhibitor therapyMyelodysplastic syndromeOral therapyCombination therapyPost-transplantMyeloid leukemiaImproved survivalSingle-armAdult patientsAzacitidineRandomized studyPhase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Bewersdorf J, Derkach A, Zeidan A, Stein E, Mauro M, Podoltsev N, Rampal R. Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. Blood 2024, 144: 6659-6659. DOI: 10.1182/blood-2024-194918.Peer-Reviewed Original ResearchConceptsDose-limiting toxicityCancer Institute Common Terminology Criteria for Adverse EventsTreatment-related adverse eventsAdverse eventsDose levelsCombination therapySpleen volumeInhibitor abemaciclibGrade 3Patients discontinued treatment due to adverse eventsNational Cancer Institute Common Terminology Criteria for Adverse EventsPhase I dose-escalation trialTreatment due to adverse eventsCommon Terminology Criteria for Adverse EventsDisease progressionRecommended phase II doseMulticenter Phase IPlanned dose levelsGrade 3 thrombocytopeniaMedian overall survivalPhase II doseBone marrow blastsBone marrow fibrosisClinically significant bleedingData cut-offImmune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab
Bewersdorf J, Hasle V, Shallis R, Thompson E, De Menezes D, Rose S, Boss I, Mendez L, Podoltsev N, Stahl M, Kewan T, Halene S, Haferlach T, Fox B, Zeidan A. Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab. Blood 2024, 144: 4585. DOI: 10.1182/blood-2024-194929.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaAnti-PD-L1 antibody durvalumabOverall response rateMyelodysplastic syndromeComplete responseBM aspiratesMyeloid leukemiaInternational Working GroupBone marrowMyelodysplastic syndromes treated with azacitidineAcute myeloid leukemia ptsWild-type acute myeloid leukemiaSecondary acute myeloid leukemiaResponse criteriaAnti-PD-L1Immune checkpoint inhibitorsTreated with azacitidineOutcomes of patientsAny-cause deathGeneration of neoantigensVariant allele frequencySusceptible to treatmentMarrow CRAdverse cytogeneticsCheckpoint inhibitorsCost-Effectiveness of Allogeneic Hematopoietic Stem Cell Transplantation Versus Consolidation Chemotherapy for Patients with Intermediate Risk Acute Myeloid Leukemia
Alhajahjeh A, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Zeidan A, Goshua G, Bewersdorf J. Cost-Effectiveness of Allogeneic Hematopoietic Stem Cell Transplantation Versus Consolidation Chemotherapy for Patients with Intermediate Risk Acute Myeloid Leukemia. Blood 2024, 144: 788. DOI: 10.1182/blood-2024-201535.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationUpfront hematopoietic stem cell transplantationDisease-free survivalAcute myeloid leukemiaIntermediate risk acute myeloid leukemiaConsolidation chemotherapyCurative therapeutic modalityOverall survivalOne-way sensitivity analysesEuropean LeukemiaNetIncremental net monetary benefitMyeloid leukemiaMortality associated with hematopoietic stem cell transplantationCost-effective strategyTherapeutic modalitiesFavorable risk AMLSalvage hematopoietic stem cell transplantationAllogeneic hematopoietic stem cell transplantationCycles of consolidation chemotherapyUS health system perspectiveDiagnosed AMLFollow-up of patientsSurvival analysisHigh-dose cytarabineLines of therapyUse of Calcineurin Inhibitor (CNI) and Eltrombopag (EPAG) Among Patients with Acquired Aplastic Anemia (AA) in the United States: Results from a Large National Database
Stempel J, Wang R, Lee A, Ma X, Podoltsev N. Use of Calcineurin Inhibitor (CNI) and Eltrombopag (EPAG) Among Patients with Acquired Aplastic Anemia (AA) in the United States: Results from a Large National Database. Blood 2024, 144: 2319. DOI: 10.1182/blood-2024-202185.Peer-Reviewed Original ResearchConceptsHorse anti-thymocyte globulinLow transfusion burdenAcquired aplastic anemiaCalcineurin inhibitor levelsCalcineurin inhibitorsSevere AARed blood cellsEltrombopag therapyTransfusion burdenMedian proportion of daysTransfusion of red blood cellsCalcineurin inhibitor agentsMedian starting doseAnti-thymocyte globulinDiagnosis to initiationTransplant-ineligible patientsBone marrow failureRare autoimmune disorderReduce transfusion requirementsBaseline red blood cellRetrospective cohort studyStudent's t-testProportion of daysBlue Cross Blue ShieldElixhauser comorbidity scoreCost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States
Potnis K, Ito S, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Zeidan A, Bewersdorf J, Goshua G. Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States. Blood 2024, 144: 3644. DOI: 10.1182/blood-2024-204312.Peer-Reviewed Original ResearchConceptsSevere aplastic anemiaTreatment of severe aplastic anemiaQuality-adjusted life yearsAplastic anemiaIncremental net monetary benefitDeterministic sensitivity analysisProbabilistic sensitivity analysesImmunosuppressive therapyNewly diagnosed severe aplastic anemiaCost-effectiveness of eltrombopagOral thrombopoietin receptor agonistPatients treated with eltrombopagUntreated severe aplastic anemiaHematopoietic stem cell transplantationCost-effective therapeutic strategyDevelopment of adverse eventsLonger-term follow-up dataRACE trialsLater-line therapyThrombopoietin receptor agonistsPhase I/II trialSecond-line therapyStem cell transplantationU.S. payer perspectiveFirst-line treatmentAddition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
Podoltsev N, Sun Z, Litzow M, Paietta E, Roberts K, Zhang Y, Racevskis J, Lazarus H, Rowe J, Arber D, Wieduwilt M, Liedtke M, Bergeron J, Wood B, Zhao Y, Wu G, Chang T, Zhang W, Pratz K, Dinner S, Frey N, Gore S, Bhatnagar B, Atallah E, Uy G, Jeyakumar D, Lin T, Willman C, DeAngelo D, Patel S, Elliott M, Advani A, Tzachanis D, Vachhani P, Roy R, Sharon E, Little R, Erba H, Stone R, Mullighan C, Tallman M, Luger S, Mattison R. Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial. Blood 2024, 144: 4211-4211. DOI: 10.1182/blood-2024-207143.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationRelapse free survivalAcute lymphoblastic leukemiaWhite blood cell countOlder ptsOverall survivalBone marrowAllogeneic hematopoietic stem cell transplantationB-lineage acute lymphoblastic leukemiaRandomized phase III trialFlow cytometryMulti-color flow cytometryStratified multivariable Cox modelsIncreased treatment toxicityPeripheral blood blastsStratified log-rank testImprovement of OSHigh dose methotrexateImproved overall survivalMedian follow-upStem cell transplantationKaplan-Meier methodPhase III trialsEstimates of OSLog-rank testEducational Impact of Live and Online Enduring CME Activities Presented at the 65th ASH Annual Meeting on Hematology/Oncology Specialists Evaluated Using Pre-/Post-Education Assessments
Worst M, Friedman H, Bomba S, Whitney M, Cameron D, Middleton D, Warren C, Kadkhoda H, Podoltsev N. Educational Impact of Live and Online Enduring CME Activities Presented at the 65th ASH Annual Meeting on Hematology/Oncology Specialists Evaluated Using Pre-/Post-Education Assessments. Blood 2024, 144: 2445-2445. DOI: 10.1182/blood-2024-208458.Peer-Reviewed Original ResearchConceptsStatistically significant improvementCME activitySickle Cell Disease AssociationAmerican Society of HematologyEducational impactPost-education assessmentsClinical care decisionsOnline CME activitiesCare of patientsLearning themesAmerican Society of Hematology Annual MeetingHealth equityCare planningSignificant improvementHealthcare teamEndurance activitiesEndurance participantsCare decisionsIndividualized careEducational portfolioIn-personClinical knowledgeSignificant levels of changesCE creditConfidence questionsEfficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)
Stempel J, Uy G, Dinner S, Gojo I, Reed D, Roy R, Byrd K, Yerrabothala S, Lai C, Doucette K, Caldwell A, Blaha O, Podoltsev N, Mendez L, Bewersdorf J, Kewan T, Wistuba I, Alatrash G, Haymaker C, Streicher H, Sharon E, Little R, Gore S, Radich J, Wood B, Zeidan A, Shallis R. Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2). Blood 2024, 144: 736. DOI: 10.1182/blood-2024-210370.Peer-Reviewed Original ResearchConceptsPhase II trialTreatment-related AEsII trialFrequent treatment-related AEsSafety run-in periodAllogeneic stem cell transplantationNo dose limiting toxicitiesRandomized phase II trialAML-2Multi-centerControl armSafety of pembrolizumabDose-limiting toxicityPD-1 inhibitionAnti-PD1 antibodyIncomplete count recoveryFLT3 wild-typeIntermediate cytogenetic riskStem cell transplantationAcute myeloid leukemiaActivated T cellsRun-in periodIntention-to-treat analysisCancer Immune MonitoringLong-term survival
Clinical Trials
Current Trials
A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
HIC ID2000032345RolePrincipal InvestigatorPrimary Completion Date02/29/2024Recruiting Participants
Academic Achievements & Community Involvement
honor Yale Cancer Center Award for Clinical Excellence
Yale School of Medicine AwardDetails02/15/2022United Stateshonor The David S. Fischer, MD Annual Award for Outstanding Teaching and Mentoring in Hematology
Yale School of Medicine AwardYale Cancer CenterDetails06/09/2021United Stateshonor The David S. Fischer, MD Annual Award for Outstanding Teaching and Mentoring in Hematology
Yale School of Medicine AwardYale Cancer CenterDetails06/14/2017United Stateshonor The David S. Fischer, MD Annual Award for Outstanding Teaching and Mentoring in Hematology
Yale School of Medicine AwardYale Cancer CenterDetails06/15/2011United States
Clinical Care
Overview
Nikolai Podoltsev, MD, PhD, is a hematologist who specializes in treating patients with acute leukemias, or cancers of the blood and bone marrow. These include acute myeloid leukemias, acute lymphoblastic leukemia, myeloid neoplasms, myeloproliferative neoplasms, and chronic myeloid leukemia.
Dr. Podoltsev also cares for patients with aplastic anemia and bone marrow failure syndromes and those with clonal hematopoiesis of indeterminate potential (CHIP), systemic mastocytosis, and hypereosinophilic syndrome. He is the director of the Hematology/Leukemia Tumor Board and represents Yale Cancer Center on National Comprehensive Cancer Network (NCCN) clinical practice guidelines panels, including the Myeloproliferative Neoplasms Panel.
Dr. Podoltsev says he appreciates the relationships he forms with patients and their families. “I enjoy helping them improve their quality of life and taking off the burden of stress when they know they are in the excellent care of our dedicated team,” he says.
Part of the Leukemia Disease Aligned Research Team (DART), Dr. Podoltsev is a principal investigator for multiple clinical trials enrolling patients with acute leukemias and myeloid malignancies.
“We have a number of clinical trials that are investigating drugs that might change the course of many malignant diseases and offering clinical trials is an important part of our mission,” he says.
Clinical Specialties
Fact Sheets
Myeloproliferative Neoplasms
Learn More on Yale MedicineMyelodysplastic Syndromes
Learn More on Yale MedicineMyelodysplastic/Myeloproliferative Neoplasms
Learn More on Yale MedicineAcute Myeloid Leukemia (AML)
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews & Links
News
- December 18, 2024
Yale research advances presented at American Society of Hematology annual meeting
- June 12, 2024
Yale Medical Oncology-Hematology Fellowship Graduation 2024
- May 28, 2024
Annual Fellows Research Day 2024
- March 25, 2024
Yale’s Post ASH Review
Get In Touch
Contacts
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.